Why this seasoned money manager sees real upside for this innovative B2B tech startup. on 10/26/2021. Learn More

Sector Expert: Ben Haynor

Feltl and Company

Image: Ben Haynor

Ben Haynor joined the Feltl & Co. research department in October 2010. Prior to joining Feltl, Haynor founded two technology startups—Taggart Communications and Spigot Games. Before launching those firms, Haynor spent five years in equity trading at RBC Capital Markets, with the last several years spent as a NASDAQ market maker. He is a CFA charterholder and a member of CFA Institute and CFA Society of Minnesota. In the most recent Wall Street Journal "Best on the Street" publication, Haynor took second in the Medical Equipment & Supplies category, and was also ranked the No. 1 stock picker by StarMine in the U.S. Health Care Equipment and Supplies sector as part of the 2013 StarMine Analyst awards. He earned a bachelor's degree in finance with a minor in management information systems, from Pennsylvania State University.

Recent Interviews

Better, Faster, Cheaper—You Can Have All Three in Medtech: Ben Haynor (3/5/14)

Given that medical technology is an easy target for payers looking to cut reimbursements, it's important for investors to find device and diagnostic companies with the greatest efficiencies. Accuracy, speed and economy command a premium multiple because these features ultimately relieve pressure on margins, improve quality and reduce patient risk and institutional liability. In this interview with The Life Sciences Report, Senior Research Analyst Ben Haynor of Feltl & Co. shares his top two medtech names, which he expects will achieve outsized gains this year. He also delivers a couple of bonus names that investors could parlay into a profitable small- and micro-cap portfolio.

Recent Quotes

"We rate DPRX a Strong Buy as Locilex would be the first approved drug for mild DFI."

— Ben Haynor, Feltl and Company (1/5/15)
more >

"The fact that CGIX was able to get a practiced sales force to take its products to market is a very big deal."

The Life Sciences Report Interview with Ben Haynor (3/5/14)
more >

"CGIX's business model and target markets are among the best in the molecular diagnostics space."

— Ben Haynor, Feltl and Company (10/2/13)
more >

"We are initiating coverage on CGIX with a Strong Buy rating."

— Ben Haynor, Feltl and Company (5/21/13)
more >

Due to permission requirements, not all quotes are shown.